Cerity Partners LLC Invests $420,000 in United Therapeutics Co. (NASDAQ:UTHR)

Cerity Partners LLC bought a new position in shares of United Therapeutics Co. (NASDAQ:UTHR) during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 1,909 shares of the biotechnology company’s stock, valued at approximately $420,000.

Several other hedge funds and other institutional investors have also made changes to their positions in UTHR. C M Bidwell & Associates Ltd. acquired a new stake in shares of United Therapeutics during the 3rd quarter worth about $91,000. Blue Trust Inc. increased its position in United Therapeutics by 10.0% during the fourth quarter. Blue Trust Inc. now owns 504 shares of the biotechnology company’s stock worth $114,000 after buying an additional 46 shares during the period. Synovus Financial Corp acquired a new position in United Therapeutics during the third quarter worth approximately $203,000. Caxton Associates LP acquired a new position in United Therapeutics during the third quarter worth approximately $213,000. Finally, B. Riley Wealth Advisors Inc. acquired a new position in United Therapeutics during the third quarter worth approximately $219,000. Institutional investors and hedge funds own 94.08% of the company’s stock.

United Therapeutics Stock Down 0.4 %

United Therapeutics stock opened at $235.95 on Friday. The company has a debt-to-equity ratio of 0.05, a current ratio of 4.41 and a quick ratio of 4.28. United Therapeutics Co. has a 1-year low of $204.44 and a 1-year high of $261.54. The company has a market cap of $11.10 billion, a PE ratio of 11.89 and a beta of 0.52. The stock’s 50 day moving average price is $233.36 and its 200 day moving average price is $228.79.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings results on Wednesday, February 21st. The biotechnology company reported $4.36 earnings per share for the quarter, beating analysts’ consensus estimates of $4.28 by $0.08. United Therapeutics had a return on equity of 17.72% and a net margin of 42.31%. The firm had revenue of $614.70 million for the quarter, compared to the consensus estimate of $575.01 million. During the same period in the previous year, the business earned $2.67 earnings per share. The company’s revenue for the quarter was up 25.1% compared to the same quarter last year. On average, sell-side analysts predict that United Therapeutics Co. will post 23.45 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts have commented on the company. Wedbush reaffirmed an “outperform” rating and set a $308.00 price target on shares of United Therapeutics in a research report on Thursday, February 22nd. Leerink Partnrs reaffirmed an “outperform” rating on shares of United Therapeutics in a research report on Monday, February 5th. Wells Fargo & Company lifted their target price on United Therapeutics from $309.00 to $325.00 and gave the company an “overweight” rating in a research note on Thursday, March 7th. The Goldman Sachs Group upgraded United Therapeutics from a “sell” rating to a “neutral” rating and lifted their target price for the company from $213.00 to $215.00 in a research note on Monday, February 12th. Finally, HC Wainwright reiterated a “buy” rating and issued a $300.00 target price on shares of United Therapeutics in a research note on Thursday, February 22nd. One research analyst has rated the stock with a hold rating and nine have given a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $294.25.

Insider Activity at United Therapeutics

In related news, EVP Paul A. Mahon sold 6,000 shares of United Therapeutics stock in a transaction that occurred on Thursday, February 15th. The stock was sold at an average price of $215.31, for a total value of $1,291,860.00. Following the sale, the executive vice president now directly owns 36,599 shares in the company, valued at $7,880,130.69. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. In other United Therapeutics news, EVP Paul A. Mahon sold 6,000 shares of the business’s stock in a transaction on Thursday, February 15th. The stock was sold at an average price of $215.31, for a total transaction of $1,291,860.00. Following the sale, the executive vice president now directly owns 36,599 shares in the company, valued at $7,880,130.69. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Martine A. Rothblatt sold 15,000 shares of the business’s stock in a transaction on Tuesday, March 19th. The stock was sold at an average price of $236.59, for a total value of $3,548,850.00. Following the sale, the chief executive officer now owns 130 shares in the company, valued at $30,756.70. The disclosure for this sale can be found here. Insiders have sold a total of 136,990 shares of company stock worth $32,239,641 over the last three months. 12.50% of the stock is currently owned by corporate insiders.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.